Europe’s drug regulator said on Friday that it could not confirm whether AstraZeneca’s COVID-19 vaccine has any influence on higher risks for unusual blood clots associated with low levels of blood platelets in women and younger adults.
The European Medicine Agency (EMA) said in a statement it was requested by the European Commission to provide a scientific opinion following initial reports of thrombosis with thrombocytopenia syndrome (TTS) linked to AstraZeneca’s COVID-19 vaccine, known as Vaxzevria.
